Logic-Based and cellular pharmacodynamic modeling of bortezomib responses in U266 human myeloma cellss

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 448-458

  Chudasama, Vaishali L ^a   Ovacik, Meric A ^a   Abernethy, Darrell R ^b   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; BORONIC ACID DERIVATIVE; PROTEIN BCL X; PYRAZINE DERIVATIVE;

ALGORITHM; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IC50; INFORMATION SCIENCE; MATHEMATICAL MODEL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIMULATION; U266 CELL LINE; DRUG EFFECTS; LOGIC; METABOLISM; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BCL-X PROTEIN; BORONIC ACIDS; BORTEZOMIB; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LOGIC; MULTIPLE MYELOMA; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 84941584652     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.224766     Document Type: Article

References (50)

1. Albert R and Wang RS (2009) Discrete dynamic modeling of cellular signaling networks. Methods Enzymol 467:281-306.
2. Berger SI and Iyengar R (2011) Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med 3:129-135.
3. Bharti AC, Donato N, and Aggarwal BB (2003a) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863-3871.
4. Bharti AC, Donato N, Singh S, and Aggarwal BB (2003b) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062.
5. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, and Aggarwal BB (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD1381 cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103:3175-3184.
6. Birtwistle MR, Mager DE, and Gallo JM (2013) Mechanistic vs. Empirical network models of drug action. CPT Pharmacometrics Syst Pharmacol 2:e72.
7. Bladé J, Cibeira MT, Fernández de Larrea C, and Rosiñol L (2010) Multiple myeloma. Ann Oncol 21 (Suppl 7):vii313-vii319.
8. Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, and Vanderkerken K (2008) Multiple myeloma-an update on diagnosis and treatment. Eur J Haematol 81:329-343.
9. Csermely P, Korcsmáros T, Kiss HJ, London G, and Nussinov R (2013) Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacol Ther 138:333-408.
10. Ge H and Qian M (2009) Boolean network approach to negative feedback loops of the p53 pathways: Synchronized dynamics and stochastic limit cycles. J Comput Biol 16:119-132.
11. Harrold JM and Abraham AK (2014) Ubiquity: A framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. J Pharmacokinet Pharmacodyn 41:141-151.
12. Harrold JM, Ramanathan M, and Mager DE (2013) Network-based approaches in drug discovery and early development. Clin Pharmacol Ther 94:651-658.
13. Harrold JM, Straubinger RM, and Mager DE (2012) Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res 72:1632-1641.
14. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, and Anderson KC (2003a) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386-8393.
15. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647.
16. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, et al. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046-1052.
17. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, et al. (2003b) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534.
18. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
19. Huang SM, Abernethy DR, Wang Y, Zhao P, and Zineh I (2013) The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci 102: 2912-2923.
20. Iyengar R, Zhao S, Chung SW, Mager DE, and Gallo JM (2012) Merging systems biology with pharmacodynamics. Sci Transl Med 4:126ps7.
21. Jusko WJ (2013) Moving from basic toward systems pharmacodynamic models. J Pharm Sci 102:2930-2940.
22. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1:a000141.
23. Karin M and Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221-227.
24. Kay BP, Hsu CP, Lu JF, Sun YN, Bai S, Xin Y, and D'Argenio DZ (2012) Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab. J Pharmacokinet Pharmacodyn 39: 577-590.
25. Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, and Onsum MD (2013) Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal 6:ra68.
26. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, and Yu H (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283-293.
27. Liu YY, Slotine JJ, and Barabási AL (2013) Observability of complex systems. Proc Natl Acad Sci USA 110:2460-2465.
28. Mager DE and Jusko WJ (2001) Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216.
29. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518.
30. Mai Z and Liu H (2009) Boolean network-based analysis of the apoptosis network: irreversible apoptosis and stable surviving. J Theor Biol 259:760-769.
31. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, et al. (2013) Model-based drug development: A rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 93:502-514.
32. Oancea M, Mani A, Hussein MA, and Almasan A (2004) Apoptosis of multiple myeloma. Int J Hematol 80:224-231.
33. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, and Yoon SS (2008) Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2:317-326.
34. Park S, Lee HJ, Jeong SJ, Song HS, Kim M, Lee HJ, Lee EO, Kim DH, Ahn KS, and Kim SH (2011) Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. Food Chem Toxicol 49:1367-1372.
35. Pillai GC, Mentré F, and Steimer JL (2005) Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 32:161-183.
36. Rhee YH, Jeong SJ, Lee HJ, Lee HJ, Koh W, Jung JH, Kim SH, and Sung-Hoon K (2012) Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells. BMC Cancer 12:28.
37. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
38. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498.
39. Saez-Rodriguez J, Alexopoulos LG, Zhang M, Morris MK, Lauffenburger DA, and Sorger PK (2011) Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res 71:5400-5411.
40. Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, et al. (2009) Modeling ERBB receptorregulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 3:1.
41. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al.; VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917.
42. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87: 1577-1584.
43. Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, Chng WJ, and Sethi G (2014) Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-kB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget 5:634-648.
44. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, and Gutkind JS (2006) Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8:733-746.
45. Thakar J, Pilione M, Kirimanjeswara G, Harvill ET, and Albert R (2007) Modeling systems-level regulation of host immune responses. PLOS Comput Biol 3:e109.
46. Veliz-Cuba A (2011) Reduction of Boolean network models. J Theor Biol 289: 167-172.
47. Wittmann DM, Krumsiek J, Saez-Rodriguez J, Lauffenburger DA, Klamt S, and Theis FJ (2009) Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling. BMC Syst Biol 3:98.
48. Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin MJ, Mehta PP, Kung PP, and Vicini P (2011) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 338: 964-973.
49. Zhang T, Li Y, Zou P, Yu JY, McEachern D, Wang S, and Sun D (2013) Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharm Drug Dispos 34:348-359.
50. Zhao S and Iyengar R (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52:505-521.